A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.

2648Background: Despite an exponential increase in the number of potential targets in the immuno-oncology (IO) field, lack of risk models to predict toxicities remains a challenge in early drug dev...